The table above summarizes the beneficial effects of SGLT2 inhibitors administration in patients with heart failure, with various grades of ejection fraction or CKD obtained in large clinical trials demonstrating that the hemodynamic effects discussed above reflect an improved clinical outcome for the patient. The gene discussed is SLC5A2; the disease is heart failure.